Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

dexcom inc. - DXCM

DXCM

Close Chg Chg %
67.06 -0.69 -1.03%

Closed Market

66.37

-0.69 (1.03%)

Volume: 2.07M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Trade Now

Company Overview: dexcom inc. - DXCM

DXCM Key Data

Open

$67.10

 Day Range

66.00 - 67.15

52 Week Range

54.11 - 93.24

 Market Cap

$25.89B

Shares Outstanding

390.02M

 Public Float

384.35M

Beta

1.48

 Rev. Per Employee

N/A

P/E Ratio

37.32

 EPS

$1.84

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

4.60M

  

DXCM Performance

1 Week
 
 -1.78%
 
1 Month
 
 1.34%
 
3 Months
 
 -1.01%
 
1 Year
 
 -14.66%
 
5 Years
 
 -28.19%
 

DXCM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 33
Full Ratings ➔

About dexcom inc. - DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DXCM At a Glance

DexCom, Inc.
6340 Sequence Drive
San Diego, California 92121
Phone 1-858-200-0200 Revenue 4.03B
Industry Medical Specialties Net Income 576.20M
Sector Health Technology 2024 Sales Growth 11.338%
Fiscal Year-end 12 / 2025 Employees 10,300
View SEC Filings

DXCM Valuation

P/E Current 37.324
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 54.614
Price to Sales Ratio 7.958
Price to Book Ratio 14.451
Price to Cash Flow Ratio 32.44
Enterprise Value to EBITDA 39.261
Enterprise Value to Sales 7.96
Total Debt to Enterprise Value 0.081

DXCM Efficiency

Revenue/Employee 391,553.398
Income Per Employee 55,941.748
Receivables Turnover 3.902
Total Asset Turnover 0.633

DXCM Liquidity

Current Ratio 1.467
Quick Ratio 1.282
Cash Ratio 0.88

DXCM Profitability

Gross Margin 60.29
Operating Margin 14.877
Pretax Margin 17.58
Net Margin 14.287
Return on Assets 9.039
Return on Equity 27.628
Return on Total Capital 12.286
Return on Invested Capital 14.219

DXCM Capital Structure

Total Debt to Total Equity 123.057
Total Debt to Total Capital 55.168
Total Debt to Total Assets 39.901
Long-Term Debt to Equity 64.706
Long-Term Debt to Total Capital 29.009
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dexcom Inc. - DXCM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.45B 2.91B 3.62B 4.03B
Sales Growth
+27.08% +18.84% +24.49% +11.34%
Cost of Goods Sold (COGS) incl D&A
768.00M 1.03B 1.34B 1.60B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
102.00M 155.90M 186.00M 217.70M
Depreciation
96.30M 144.10M 147.40M 181.20M
Amortization of Intangibles
5.70M 11.80M 38.60M 36.50M
COGS Growth
+18.78% +34.66% +29.71% +19.38%
Gross Income
1.68B 1.88B 2.28B 2.43B
Gross Income Growth
+31.28% +11.61% +21.60% +6.61%
Gross Profit Margin
+68.63% +64.46% +62.97% +60.29%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.41B 1.48B 1.68B 1.83B
Research & Development
604.20M 484.20M 497.70M 545.70M
Other SG&A
810.50M 1.00B 1.19B 1.29B
SGA Growth
+44.27% +4.93% +13.39% +8.82%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.50M
-
EBIT after Unusual Expense
264.30M 391.20M 597.70M 600.00M
Non Operating Income/Expense
9.90M 18.20M 133.00M 128.00M
Non-Operating Interest Income
- - 135.00M 134.20M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
100.30M 18.60M 20.30M 19.00M
Interest Expense Growth
+18.42% -81.46% +9.14% -6.40%
Gross Interest Expense
100.30M 18.60M 20.30M 19.00M
Interest Capitalized
- - - -
-
Pretax Income
173.90M 390.80M 710.40M 709.00M
Pretax Income Growth
-22.71% +124.73% +81.78% -0.20%
Pretax Margin
+7.10% +13.43% +19.61% +17.58%
Income Tax
19.20M 49.60M 168.90M 132.80M
Income Tax - Current - Domestic
14.00M 58.70M 167.20M 173.90M
Income Tax - Current - Foreign
10.10M 12.50M 56.70M 2.70M
Income Tax - Deferred - Domestic
2.10M (21.90M) (79.10M) (57.20M)
Income Tax - Deferred - Foreign
(7.00M) 300.00K 24.10M 13.40M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
154.70M 341.20M 541.50M 576.20M
Minority Interest Expense
- - - -
-
Net Income
154.70M 341.20M 541.50M 576.20M
Net Income Growth
-68.66% +120.56% +58.70% +6.41%
Net Margin Growth
+6.32% +11.73% +14.95% +14.29%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
154.70M 341.20M 541.50M 576.20M
Preferred Dividends
- - - -
-
Net Income Available to Common
154.70M 341.20M 541.50M 576.20M
EPS (Basic)
0.3999 0.8762 1.4028 1.4639
EPS (Basic) Growth
-69.41% +119.10% +60.10% +4.36%
Basic Shares Outstanding
386.80M 389.40M 386.00M 393.60M
EPS (Diluted)
0.3864 0.7981 1.3022 1.424
EPS (Diluted) Growth
-69.47% +106.55% +63.16% +9.35%
Diluted Shares Outstanding
400.40M 427.50M 425.50M 412.70M
EBITDA
367.80M 547.10M 783.70M 817.70M
EBITDA Growth
+0.33% +48.75% +43.25% +4.34%
EBITDA Margin
+15.02% +18.80% +21.64% +20.28%

Snapshot

Average Recommendation BUY Average Target Price 86.308
Number of Ratings 33 Current Quarters Estimate 0.47
FY Report Date 03 / 2026 Current Year's Estimate 2.473
Last Quarter’s Earnings 0.65 Median PE on CY Estimate N/A
Year Ago Earnings 2.06 Next Fiscal Year Estimate 2.984
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 22 28 24
Mean Estimate 0.47 0.60 2.47 2.98
High Estimates 0.55 0.68 2.68 3.40
Low Estimate 0.39 0.54 2.29 2.59
Coefficient of Variance 8.92 5.06 3.68 6.22

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 24 23 21
OVERWEIGHT 4 4 4
HOLD 5 6 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Dexcom Inc. - DXCM

Date Name Shares Transaction Value
Jul 18, 2025 Mark G. Foletta Director 53,879 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.17 per share 4,588,874.43
Jul 18, 2025 Mark G. Foletta Director 53,871 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $86.03 per share 4,634,522.13
Jul 18, 2025 Michael Jon Brown EVP, Chief Legal Officer 94,602 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $86.03 per share 8,138,610.06
Mar 21, 2025 Bridgette P. Heller Director 22,997 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.33 per share 1,617,379.01
Mar 17, 2025 Kevin Ronald Sayer Chairman, CEO & President; Director 372,029 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.38 per share 26,183,401.02
Mar 17, 2025 Jacob S. Leach EVP, Chief Operating Officer 313,497 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.38 per share 22,063,918.86
Mar 17, 2025 Jereme M Sylvain EVP, Chief Financal Officer 123,481 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.38 per share 8,690,592.78
Mar 17, 2025 Sadie M Stern EVP, Chief HR Officer 115,805 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.38 per share 8,150,355.90
Mar 12, 2025 Michael Jon Brown EVP, Chief Legal Officer 118,602 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Jacob S. Leach EVP, Chief Operating Officer 327,573 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Jereme M Sylvain EVP, Chief Financal Officer 142,482 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Jereme M Sylvain EVP, Chief Financal Officer 139,812 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $73.22 per share 10,237,034.64
Mar 12, 2025 Jereme M Sylvain EVP, Chief Financal Officer 136,609 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.04 per share 10,114,530.36
Mar 12, 2025 Jereme M Sylvain EVP, Chief Financal Officer 135,482 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.7 per share 10,120,505.40
Mar 12, 2025 Sadie M Stern EVP, Chief HR Officer 126,981 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Renée D. Galá Director 5,720 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Dexcom Inc. in the News